AA amyloidosis associated with hepatitis B

Nephrology Dialysis Transplantation

Volumn 26, Issue 7, 2011, Pages 2407-2412

  Saha, Abhijeet ^a   Theis, Jason D ^b   Vrana, Julie A ^b   Dubey, Nand K ^a   Batra, Vineeta V ^c   Sethi, Sanjeev ^b  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

^b MAYO CLINIC   (United States)

^c G B PANT HOSPITAL   (India)

Author keywords

AA amyloid; hepatitis B; mass spectrometry; proteomics; SAA variant

Indexed keywords

ALBUMIN; CALCIUM; CEFTRIAXONE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LISINOPRIL; LOSARTAN; PREDNISOLONE; SERUM AMYLOID A; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; VANCOMYCIN; VITAMIN K GROUP;

ADOLESCENT; ANTIGEN DETECTION; ARTICLE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FAMILIAL AMYLOIDOSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; LASER MICRODISSECTION; MALE; MASS SPECTROMETRY; MESANGIUM CELL; NEPHROTIC SYNDROME; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SEPSIS; SHOCK;

AMINO ACID SEQUENCE; AMYLOIDOSIS; CHILD; CHROMATOGRAPHY, LIQUID; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; KIDNEY GLOMERULUS; LASERS; MALE; MICRODISSECTION; MOLECULAR SEQUENCE DATA; NEPHROTIC SYNDROME; PROGNOSIS; SERUM AMYLOID A PROTEIN; TANDEM MASS SPECTROMETRY;

EID: 79959985544     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr224     Document Type: Article

References (25)

1. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006; 17: 3458-3471. (Pubitemid 44865288)
2. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596. (Pubitemid 36951371)
3. Lachmann HJ, Goodman HJB, Gilbertson JA et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371. (Pubitemid 46883770)
4. Bilginer Y, Akpolat T, Ozen S. Renal amyloidosis in children. Pediatr Nephrol 2011; 6: 1-13.
5. Duarte C, Gomes C, Correia A et al. Renal amyloidosis: an uncommon complication of juvenile idiopathic arthritis. Clin Rheumatol 2006; 25: 548-549. (Pubitemid 44137633)
6. Sethi S, Fervenza FC, Miller D et al. Recurrence of amyloidosis in a kidney transplant. Am J Kidney Dis 2010; 56: 394-398.
7. Sethi S, Theis JD, Leung N et al. Mass spectrometry based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5: 2180-2187.
8. Vrana JA, Gamez JD, Madden BJ et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957-4959.
9. Benson MD, James S, Scott K et al. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int 2008; 74: 218-222. (Pubitemid 351915083)
10. Larsen CP,Walker PD,Weiss DTet al. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int 77: 816-819.
11. Murphy CL, Wang S, Kestler D et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis 2010; 56: 1100-1107.
12. Choi NH, Nakano Y, Tobe T et al. Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement. Int Immunol 1990413-417. (Pubitemid 20170081)
13. Keller A, Nesvizhskii AI, Kolker E et al. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002; 74: 5383-5392. (Pubitemid 35215372)
14. Nesvizhskii AI, Keller A, Kolker E et al. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003; 75: 4646-4658. (Pubitemid 37082259)
15. Møyner K, Sletten K, Husby G et al. An unusually large (83 amino acid residues) amyloid fibril protein AA from a patient with Waldenström's macroglobulinaemia and amyloidosis. Scand J Immunol 1980; 11: 549-554. (Pubitemid 10105769)
16. Obici L, Raimondi S, Lavatelli F et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthr Care Res 2009; 61: 1435-1440.
17. Smith ME, Ansell BM, Bywaters EG. Mortality and prognosis related to amyloidosis of Still's disease. Ann Rheum Dis 1968; 27: 137-145.
18. Chugh KS, Datta BN, Singhal PC et al. Pattern of renal amyloidosis in Indian patients. Postgrad Med J 1981; 57: 31-35. (Pubitemid 11141962)
19. Cao Y, Zhang Y, Wang S et al. Simultaneous occurrence of hepatitis C virus-associated glomerulonephritis and AL amyloidosis. Nephrol Dial Transplant 2009; 24: 2943-2945.
20. Kishida D, Okuda Y, OnishiMet al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 2011; 2: 215-218.
21. Turkmen K, Anil M, Solak Yet al. A hepatitis C-positive patient with new onset of nephrotic syndrome and systemic amyloidosis secondary to common variable immunodeficiency. Ann Saudi Med 2010; 30: 401-403.
22. Lannergård A, Larsson A, Kragsbjerg P et al. Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. Scand J Clin Lab Invest 2003; 63: 267-272. (Pubitemid 37006434)
23. Rodriguez FJ, Gamez JD, Vrana JA et al. Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest 2008; 88: 1024-1037.
24. Murphy CL, Wang S, Kestler DP et al. AA amyloidosis associated with a mutated serum amyloid A4 protein. Amyloid 2009; 16: 84-88.
25. Dember LM, Hawkins PN, Hazenberg BPC et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356: 2349-2360 (Pubitemid 46883769)